ARO RAGE
Alternative Names: ARO-RAGELatest Information Update: 24 May 2024
At a glance
- Originator Arrowhead Pharmaceuticals
- Class Antiasthmatics; Small interfering RNA
- Mechanism of Action Advanced glycosylation end product receptor antagonists; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Asthma
- Preclinical Obstructive airway disorders
Most Recent Events
- 20 May 2024 Adverse events and efficacy data from the phase I/II trial in Asthma released by Arrowhead Pharmaceuticals
- 20 May 2024 Arrowhead Pharmaceuticals plans a phase II trial in Asthma in late 2024
- 17 May 2024 Adverse events and pharmacokinetics data from the phase I/II ARO-RAGE trial in Asthma presented at the 120th International Conference of the American Thoracic Society (ATS-2024)